AstraZeneca Thursday signed a co-commercialization agreement with Parsippany, N.J.-based Daiichi Sankyo, Inc. worth $825 million.
According to the agreement, Daiichi Sankyo will pay AstraZeneca $200 million upfront and follow-up payments up to $625 million to handle manufacturing and sales of Movantik (naloxegol), a once-daily pill for people with opioid-induced constipation (OIC). AstraZeneca will oversee manufacturing and sales and both companies will be involved in commercial activities.
“We are delighted to collaborate with Daiichi Sankyo to expand our commercialization efforts in the U.S. in order to get this important medicine to the large number of patients suffering with opioid-induced constipation,” said Paul Hudson, president of AstraZeneca U.S. and executive vice president, North America, in a statement.
The compound has received marketing authorization in Europe for the treatment of OIC under the name Moventig.